Lynx1 Capital Management LP

13D and 13G Filings

Issuer % of Class Filed
Schedule 13D · 2 securities · may seek to influence control
Passage BIO, Inc. 13D
PASG · 702712100
21.0% 7/2/2026
Event 6/25/2026
Neuphoria Therapeutics Inc. 13D/A
NEUP · 64136E102
16.3% 12/29/2025
Event 12/26/2025
Schedule 13G · 10 securities · passive
Precision BioSciences, Inc. 13G/A
DTIL · 74019P207
9.9% 11/16/2026
Event 9/30/2026
Agios Pharmaceuticals, Inc. 13G/A
AGIO · 00847X104
0.8% 11/16/2026
Event 9/30/2026
TScan Therapeutics, Inc. 13G/A
TCRX · 89854M101
13.1% 8/14/2026
Event 6/30/2026
Stoke Therapeutics, Inc. 13G/A
STOK · 86150R107
6.5% 8/14/2026
Event 6/30/2026
C4 Therapeutics, Inc. 13G/A
CCCC · 12529R107
10.0% 8/14/2026
Event 6/30/2026
iBio, Inc. 13G
IBIO · 451033708
5.4% 8/14/2026
Event 6/30/2026
GH Research PLC 13G/A
GHRS · G3855L106
19.3% 8/14/2026
Event 6/30/2026
Allogene Therapeutics, Inc. 13G/A
ALLO · 019770106
0% 5/15/2026
Event 12/31/2025
Korro Bio, Inc. 13G/A
KRRO · 500946108
10.7% 4/2/2026
Event 3/31/2026
Cullinan Therapeutics, Inc. 13G/A
CGEM · 230031106
9.8% 11/14/2025
Event 9/30/2025

Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.